Methotrexate increases expression of cell cycle checkpoint genes via JNK activation

Arthritis and Rheumatism

Volumn 64, Issue 6, 2012, Pages 1780-1789

  Spurlock III, Charles F ^a   Tossberg, John T ^b   Fuchs, Howard A ^a   Olsen, Nancy J ^c   Aune, Thomas M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b ArthroChip   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELL PROTEIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; MESSENGER RNA; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 9; PROTEIN; PROTEIN P21; PROTEIN P53; RANGAP1 PROTEIN; REACTIVE OXYGEN METABOLITE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CLINICAL ARTICLE; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; T LYMPHOCYTE ACTIVATION; TISSUE CULTURE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL CYCLE CHECKPOINTS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; METHOTREXATE; MIDDLE AGED; REACTIVE OXYGEN SPECIES;

EID: 84861803251     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34342     Document Type: Article

References (49)

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part 1. Arthritis Rheum 2008; 58: 15-25.
2. Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Helmick CG,. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum 2007; 56: 1397-407.
3. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721-30.
4. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 28: 818-22.
5. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA,. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094-104.
6. Gubner R, August S, Ginsberg V,. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-82.
7. Cronstein BN,. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163-72.
8. Phillips DC, Woollard KJ, Griffiths HR,. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003; 138: 501-11.
9. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-10.
10. Seeger DR, Cosulich DB, Smith JM, Hultquist ME,. Analogs of pteroylglutamic acid. III. 4-amino derivatives. J Am Chem S IIIoc 1949; 71: 1753-8.
11. Farber S, Diamond L, Mercer RD, Sylvester RF, Wolff JA,. Temporary remissions in acute leukemia in children produced by folic antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948; 238: 787-93.
12. Tian H, Cronstein BN,. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65: 168-73.
13. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-41.
14. Chan SLC, Cronstein BN,. Methotrexate-how does it really work? Nat Rev Rheumatol 2010; 6: 175-8.
15. Maas K, Westfall M, Pietenpol J, Olsen NJ, Aune T,. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis Rheum 2005; 52: 1047-57.
16. Shao L, Fukii H, Ines C, Oishi H, Goronzy JJ, Weyand CM,. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med 2009; 206: 1435-49.
17. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000; 287: 1824-7.
18. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993: 817-25.
19. Matsuoka S, Huang M, Elledge SJ,. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282: 1893-7.
20. Spurlock CF III, Aune ZT, Tossberg JT, Collins PL, Aune JP, Huston JW III, et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum 2011; 63: 2606-16.
21. Fuchs SY, Adler V, Pincus MR, Ronai Z,. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A 1998; 95: 10541-6.
22. Topisirovic I, Gutierrez GJ, Chen M, Appella E, Borden KL, Ronai ZA,. Control of p53 multimerization by Ubc13 is JNK-regulated. Proc Natl Acad Sci U S A 2009; 106: 12676-81.
23. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001; 21: 2743-54.
24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
25. Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 1995; 34: 421-8.
26. Bou G, Villasis-Keever A, Paya CV,. Detection of JNK and p38 activation by flow cytometry analysis. Anal Biochem 2003; 317: 147-55.
27. She QB, Chen N, Dong Z,. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 2000; 275: 20444-9.
28. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
29. Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rodevand E, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 671-6.
30. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-34.
31. Moat SJ, Clarke ZL, Madhavan AK, Lewis MJ, Lang D,. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. Eur J Pharmacol 2006; 530: 250-8.
32. Green DR, Droin N, Pinkoski M,. Activation-induced cell death in T cells. Immunol Rev 2003; 193: 70-81.
33. Shao L, Fujii H, Colmegna I, Oishi H, Goronzy JJ, Weyand CM,. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med 2009; 206: 1435-49.
34. Shao L, Goronzy JJ, Weyand CM,. DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis. EMBO Mol Med 2010; 2: 415-27.
35. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen NJ, et al. Molecular portrait of human autoimmune disease. J Immunol 2002; 169: 5-9.
36. Pumiglia KM, Decker SJ,. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A 1997; 94: 448-52.
37. Toyoshima H, Hunter T,. p27, a novel inhibitor of G1 cyclin-CdK protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
38. Waldman T, Lengauer C, Kinzler KW, Vogelstein B,. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-6.
39. 2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 2002; 4: 993-7.
40. Arnaoutov A, Dasso M,. The Ran GTPase regulates kinetochore function. Dev Cell 2003; 5: 99-111.
41. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S,. Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli. Science 2006; 311: 1141-6.
42. Zhang XP, Liu F, Wang W,. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci U S A 2011; 108: 8990-5.
43. Chen W, Li L, Brod T, Saeed O, Thabet S, Jansen T, et al. The role of increased guanosine triphosphate cyclohydrolase-1 expression and tetrahydrobiopterin levels upon T cell activation. J Biol Chem 2011; 286: 13846-51.
44. Seemayer CA, Kuchen S, Neidhart M, Kuenzler P, Rihoskova V, Neumann E, et al. p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. Ann Rheum Dis 2003; 62: 1139-44.
45. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR,. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997; 94: 10895-900.
46. Deng X, Ljunggren-Rose A, Mass K, Subramaniam S,. Defective ATM-p53-mediated apoptotic pathway in multiple sclerosis. Ann Neurol 2005; 58: 577-84.
47. Jackson SP, Bartek J,. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-8.
48. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196: 756-63.
49. Pincus T, Callahan LF,. Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841-5.